Longitudinal moca cognitive assessment4/17/2024 ![]() Cardiopulmonary comorbidities had the largest impact on a patient’s Cognivue score (78.0 average score for those without this comorbidity vs 67.1 average score for those with P<0.001). Overall, an increased co-morbidity count significantly decreased subjects’ Cognivue scores (correlation -0.21 P=0.01). In the sub analysis, medical records of 203 subjects were analyzed. The SLUMS test demonstrated greater variability in regression scores across test sessions (test session 1&2: regression fit: R 2 = 0.63 r = 0.79 test session 1&3: regression fit: R 2 = 0.43 r = 0.65 test session 1&4: regression fit: R 2 = 0.64 r = 0.80). Results: Among these 238 patients, Cognivue demonstrated similar linear regression scores across comparisons (test session 1&2: regression fit: R 2 = 0.76 r = 0.87 test session 1&3: regression fit: R 2 = 0.72 r = 0.85 test session 1&4: regression fit: R 2 = 0.73 r = 0.86). In a separate sub-analysis, the medical records of those subjects were analyzed to determine the correlation, if any, between comorbidities or medication usage and Cognivue score. An analysis of linear regression test-retest reliability was performed for both tests. These were followed by sessions at 6, 12, and 18 months. Sessions 1 and 2 were 1 week apart and were in addition to the FDA sessions. They underwent the Cognivue test and SLUMS at up to 5 sessions over the course of 18 months. Methods: 238 subjects from the FDA-regulated clinical study for device clearance enrolled in the longitudinal study. Further follow-up long-term data analysis within this cohort was done to study Cognivue’s test re-test reliability vs SLUMS over time. ![]() Louis University Mental Status (SLUMS) and other neuropsychological tests, and superior test re-test reliability compared to SLUMS across 2 sessions, 1 to 2 weeks apart (Cognivue regression fit: R 2 = 0.81, r = 0.90) SLUMS regression fit: R 2 = 0.67, r = 0.82). In an FDA-regulated clinical study for device clearance, Cognivue demonstrated good agreement with the St. Background: Cognivue ® is an FDA-cleared computerized testing tool designed to assess early signs of cognitive impairment.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |